About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:7261455
Allelic
Composition
Cxcr4tm2Yzo/Cxcr4tm2Yzo
Tg(Myh6-cre)2182Mds/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cxcr4tm2Yzo mutation (1 available); any Cxcr4 mutation (32 available)
Tg(Myh6-cre)2182Mds mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• most mice die between 12-14 months of age

cardiovascular system
• at 6 months, but not 2 months, mice show progressive interstitial/perivascular fibrosis
• hearts from 5-month-old mice have a higher number of mitochondria and these mitochondria are smaller than in controls
• however, stroke volume and cardiac output are normal and heart rate is not significantly affected
• at 6 months, but not 2 months, hearts show significant cardiac myocyte hypertrophy
• by 6 months of age, mice have a 15% increase in heart weight to body weight ratio and a 50% increase by 12 months of age
• at 6 months, but not 2 months, hearts show significant cardiac myocyte hypertrophy
• 4-month-old mice show elevated levels of atrial natriuretic factor (ANF), a maker of cardiac hypertrophy
• at 6 months, but not 2 months, mice show progressive interstitial/perivascular fibrosis
• 12-month-old mice exhibit a 3-fold decline in the maximum rate of change in left ventricular pressure (dp/dt max) and a more than 2.5-fold decline in ejection fraction
• 4-month-old mice exhibit a 2.5-fold decrease in contractility and a significant decrease in ejection fraction
• mice show an increase in left ventricular end-diastolic volume and an increase in end-systolic volume, indicating a decline in systolic pressures over time
• mice develop progressive cardiomyopathy, showing mild cardiomyopathy as early as 4 months of age
• progressive cardiac dysfunction leads to clinical hear failure by 12 months of age

growth/size/body
• by 6 months of age, mice have a 15% increase in heart weight to body weight ratio and a 50% increase by 12 months of age
• at 6 months, but not 2 months, hearts show significant cardiac myocyte hypertrophy
• 4-month-old mice show elevated levels of atrial natriuretic factor (ANF), a maker of cardiac hypertrophy

homeostasis/metabolism
• mice are more sensitive to catecholamine exposure via an acute isoproterenol challenge, showing a greater increase in ejection fraction and dp/dt max; mice show a robust response to isoproterenol and overcome their baseline deficits to eventually reach control levels, however the effect is only transient and cardiac function goes back to baseline within minutes

muscle
• at 6 months, but not 2 months, hearts show significant cardiac myocyte hypertrophy
• 12-month-old mice exhibit a 3-fold decline in the maximum rate of change in left ventricular pressure (dp/dt max) and a more than 2.5-fold decline in ejection fraction
• 4-month-old mice exhibit a 2.5-fold decrease in contractility and a significant decrease in ejection fraction
• mice develop progressive cardiomyopathy, showing mild cardiomyopathy as early as 4 months of age

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
cardiomyopathy DOID:0050700 J:289614
congestive heart failure DOID:6000 J:289614


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Copyright, and Privacy Statement
Send questions and comments to User Support.
last database update
01/24/2023
MGI 6.22
The Jackson Laboratory